iBio, Inc. (NYSEMKT:IBIO – Get Free Report) rose 13.1% on Wednesday . The stock traded as high as $4.37 and last traded at $3.89. Approximately 2,168,577 shares were traded during trading, an increase of 1,816% from the average daily volume of 113,212 shares. The stock had previously closed at $3.44.
iBio Stock Down 3.3 %
The company has a debt-to-equity ratio of 0.04, a current ratio of 0.91 and a quick ratio of 0.91. The business has a 50-day simple moving average of $2.96 and a two-hundred day simple moving average of $2.55.
About iBio
iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.
Featured Articles
- Five stocks we like better than iBio
- How to trade penny stocks: A step-by-step guide
- 2 Stocks Riding the Dominance of America’s Natural Gas Exports
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Buffett’s on the Sidelines – Should You Follow?
- How to Invest in Blue Chip Stocks
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
